Lilly Asia Ventures

Lilly Asia Ventures occupies an unusual position in the global biopharma capital landscape. Despite the name and origin, the firm operates as an independent biomedical venture firm rather than as a captive corporate venture arm, with a mandate to deploy across the full Asian biotech ecosystem and increasingly into transpacific opportunities. The Shanghai base gives the firm direct access to one of the most rapidly maturing biotech ecosystems in the world, and the independence from traditional corporate venture constraints means that LAV competes for deals on commercial venture terms rather than on strategic ones. For founders building AI-driven drug discovery platforms or therapeutics with Asian commercial relevance, LAV is one of the most credible specialist partners available.

The investment thesis is anchored in biotech, pharma and therapeutics, diagnostics, and medical devices, with explicit AI focus reflecting the firm’s view that AI-driven drug discovery has reached the point where it can underwrite credible therapeutic platform companies. The Insilico Medicine investment, referenced in the firm’s profile, is the clearest public expression of this view; Insilico operates as one of the more advanced AI-driven drug discovery platforms in the global market, with a pipeline of AI-generated therapeutic candidates progressing through clinical development. Stage flexibility is a deliberate feature, with the firm willing to engage from pre-seed and seed through Series A, B, and C, which means LAV can be a long-term capital partner across multiple rounds in companies where the fund develops conviction. The geographic emphasis is China and broader Asia, but the firm has been increasingly active in transpacific deals where Asian commercial or scientific relevance is part of the company’s plan.

The portfolio detail provided in the source is limited, but Insilico Medicine alone is a sufficient reference point to understand the firm’s posture on AI-enabled biotech. Founders building therapeutics platforms with credible scientific basis and a meaningful AI or computational layer should treat LAV as one of the natural specialist investors to engage. Founders building purely software-only AI tools without a therapeutic or pipeline angle will find a smaller surface area of fit, as the firm is fundamentally a biomedical investor.

Check sizes typically run between five and twenty-five million dollars, with the firm taking meaningful positions across the full stage range. Geographic flexibility is a feature; the Shanghai base does not preclude US or European company engagement, particularly where the company’s plan includes Asian clinical trials, Asian commercial partnerships, or Asian co-development. There is no published hard revenue requirement, which is appropriate for therapeutics and platform biotech where the relevant diligence currency is scientific evidence, clinical progress, and platform validation rather than commercial traction. The firm has a long enough operating history to credibly engage at multiple stages, which is uncommon among Asia-anchored biotech specialists.

The team is partner-driven with deep biomedical and pharma experience, and decision-making is structured around the firm’s investment committee. Founders should expect rigorous scientific diligence, particularly on platform claims and clinical pipeline assumptions, and a multi-meeting process that frequently includes scientific advisor review. Post-investment engagement is typically active, with the firm providing genuine value in Asian commercial and regulatory navigation, including connections to Chinese clinical sites, regulatory advisors, and potential pharma partners across the region.

Warm introductions through existing LAV portfolio CEOs are the most reliable path in, followed by referrals from US and European biotech investors who frequently syndicate with the firm on transpacific deals. Senior academic founders affiliated with leading Asian or US research institutions, and pharma business development executives with Asia experience, are also productive referral sources. Cold inbound is read but converts more reliably when the company has a specific Asian angle, whether commercial, clinical, or scientific, that maps directly to the firm’s mandate.

Founders should approach LAV when the company is genuinely biomedical, when there is a credible AI or platform angle in drug discovery, diagnostics, or therapeutics, and when there is a meaningful Asian dimension to the company’s plan, whether through clinical trials, commercial markets, or scientific collaboration. LAV is not the right fit for software-only digital health without a therapeutic basis, nor for founders with no Asian operational interest who are looking primarily for US or European capital. For the right founder, LAV is one of the most strategically valuable Asia-anchored partners available, with the scientific depth and commercial reach to support a global biotech across its full life cycle.